Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...

A new drug from Eli Lilly & Co. appears to be a powerful weight-loss aid.If further studies can confirm it works and show that its effects last, health insurers should pay for the treatment.

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Eli Lilly (LLY 0.82%) is doing the same with Mounjaro and Zepbound. ... Investors should keep their eyes on Roche; it could eventually be a formidable player in the obesity drug market.

Zinger Key Points. The global GLP-1 market is projected to reach $200 billion by 2031, with 68% from obesity drug sales. Novo Nordisk and Eli Lilly are expected to retain 66% of the market despite ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Eli Lilly's anti-obesity drug Zepbound ... the 6.6 million Americans who meet the SELECT criteria would equate to a US addressable market of over $50 billion at $8,000 per patient per year and $33 ...